Panel Presentation Details | |
Title: | Dermatology Innovation: Addressing Physician and |
Day: | |
Time: | |
Registration Link: | https://wsw.com/webcast/lifesci/panel9/2316951 |
Title: | Executing a Successful Product Launch During a Pandemic |
Day: | |
Time: | |
Registration Link: | https://wsw.com/webcast/lifesci/panel14/2387307 |
The format will be a virtual presentation with the opportunity for Q&A at the conclusion.
About
In
With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI™ (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for adults with the pimples and bumps of rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.
For more information about
CONTACT:
646-889-1200
jallaire@lifesciadvisors.com
Chief Financial Officer
908-731-6180
Andrew.Saik@vynetx.com
Source:
2021 GlobeNewswire, Inc., source